TMCnet News

Thompson Street Capital Partner's Isto Biologics Merges with Advanced Biologics/Biologica Technologies
[October 25, 2023]

Thompson Street Capital Partner's Isto Biologics Merges with Advanced Biologics/Biologica Technologies

Thompson Street Capital Partners (TSCP), a private equity firm based in St. Louis, today announced the merger of Isto Biologics, a portfolio company of TSCP and a global leader in regenerative and autologous therapies, and Advanced Biologics (Biologica Technologies). Terms of the transaction were not disclosed.

The merger will expand Isto's growing portfolio of bone grafts and seamlessly integrate Advanced Biologics' proprietary products alongside Influx™, Isto's esteemed line of cortical fiber allografts.

"We are delighted to welcome the entire Advanced Biologics team to Isto Biologics," said Donald Brown, CEO of Isto Biologics. "This merger brings together the best of both companies' expertise and a shared commitment to help patients heal faster."

Isto Biologics has maintained a commercial partnership with Advanced Biologics since 2020, catalyzed by the development of Isto's Integrative Bone Matrix, SPARCTM. SPARCTM is a novel inductive bone matrix that stemmed from Advanced Biologics' proprietary tissue processing method used in their flagship product OsseoGEN. SPARCTM is known for its increased levels of osteoinductive, chemotactic, angiogenic and proliferative growth factors.

The integration of Advanced Biologics' product commercialization initiatives into Isto's growing allograft portfolio provides a unique opportunity to help patients heal fast and enable both customer bases to benefit from the broadened product.

"With this merger, our combined team now brings greater clinical expertise and deeper customer support to provide our surgeon champions with the best products available on the market," said Amit Govil, President of Advanced Biologic.

"Over the past four years, our collaboration with Advanced Biologics has been impressive," said Harry Holiday, Chairman of the Board at Isto Biologics and Managing Director at Thompson Street Capital Partners. "Investing in Advanced Biologics and embarking on this strategic combination amplifies both Isto's and Advanced Biologics' comprehensive biologics portfolios, paving a path forward for continued growth and patient healing."

About Thompson Street Capital Partners

Thompson Street Capital Partners (TSCP) is a St. Louis-based private equity firm focused on investing in founder-led middle market businesses. We have acquired more than 200 companies in the Life Sciences & Healthcare Services, Software & Technology and Business Services & Consumer Products sectors and have managed more than $4.5 billion since being founded in 2000. TSCP partners with management teams to increase value by accelerating growth, both organically and via complementary acquisitions.

About Isto Biologics

Isto Biologics is a leading biologics and cellular therapy company in the orthopedic space. Isto Biologics is focused on Helping Patients Heal Faster™ through innovative solutions for bone regeneration and cell-based therapies. The company's flagship product offerings include the market-leading Magellan® Autologous Platelet Separator, and bone-growth products including InQu® Bone Graft Extender & Substitute, and the Influx™ product family. For more information, visit

About Advanced Biologics/Biologica Technologies

Advanced Biologics (ABC) is a 3-time, Orthopedics This Week - New Technology Award winning, biologics company focused on developing innovative and clinically relevant biologic solutions across a wide degree of medical specialties. To better serve customers, Advanced Biologics created Biologica Technologies in 2015 as a separate, stand-alone company to serve as the sales, marketing, and clinical research group. Advanced Biologics' core proprietary technology is the ability to access intracellular growth factors (GFs) found within allograft tissue. ProteiOS® growth factor and OsseoGEN® cellular bone matrix are among the first products utilizing this technology and possess the highest amount of GFs within their respective biologic categories. The company is privately-held and headquartered in Carlsbad, CA.

[ Back To's Homepage ]